|
FY2026
12 months to Mar 31, 2026
|
FY2025
12 months to Mar 31, 2025
|
FY2024
12 months to Mar 31, 2024
|
FY2023
12 months to Mar 31, 2023
|
FY2022
12 months to Mar 31, 2022
|
|
|---|---|---|---|---|---|
| Revenue | |||||
| Cost of revenue | |||||
| Gross profit/(loss) | |||||
| Operating expenses: | |||||
| Selling and marketing expenses | |||||
| General and administrative expenses | |||||
| Research and development | |||||
| Total operating expenses | |||||
| Total loss from operations | |||||
| Interest income | |||||
| Interest expense | |||||
| Investment income / (loss) | |||||
| Foreign currency exchange loss | |||||
| Investment impairment loss | |||||
| Credit loss impairment | |||||
| Other income (expenses), net | |||||
| Loss before income taxes from continuing operations | |||||
| Income tax (expense)/credit | |||||
| Net loss from continuing operations | |||||
| Net loss | |||||
| Other comprehensive income/(loss): | |||||
| Foreign currency translation adjustment | |||||
| Total comprehensive loss | |||||
| Net loss ordinary share, basic | |||||
| Net loss per ordinary share from continuing operation , basic | |||||
| Net loss per ordinary share from continuing operation , diluted | |||||
| Net loss per ordinary share from discontinued operation , basic | |||||
| Net loss per ordinary share from discontinued operation , diluted | |||||
| Weighted average number of ordinary shares, basic | |||||
| Weighted average number of ordinary shares, diluted | |||||
Loading...